Index of reports
> Cases with Myelodysplastic Syndrome (69)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Vincristine where reactions include myelodysplastic syndrome. The selected reports were submitted to the FDA during the sample period of about a year.
Reports 1 - 30 of 69 Next >>
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from Denmark on 2012-08-14
Patient:
Reactions: Transplant Failure, Cardiac Failure, Myelodysplastic Syndrome, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Etoposide
Indication: Mantle Cell Lymphoma
Melphalan Hydrochloride
Indication: Mantle Cell Lymphoma
Cyclophosphamide
Indication: Mantle Cell Lymphoma
Vincristine
Indication: Mantle Cell Lymphoma
Prednisolone
Indication: Mantle Cell Lymphoma
Cytarabine
Indication: Mantle Cell Lymphoma
Carmustine
Indication: Mantle Cell Lymphoma
Doxorubicin HCL
Indication: Mantle Cell Lymphoma
Mabthera
Indication: Mantle Cell Lymphoma
Possible Vincristine side effects in
Reported by a physician from Denmark on 2012-08-09
Patient:
Reactions: Myelodysplastic Syndrome
Drug(s) suspected as cause:
Cyclophosphamide
Vincristine
Dosage: day 1; cycle 5
Prednisolone
Dosage: on days 1-5; cycle 1
Indication: Mantle Cell Lymphoma
Rituximab
Dosage: in cycle 6 on day 9
Melphalan Hydrochloride
Dosage: day 6; beam/c regimen
Indication: Mantle Cell Lymphoma
Cyclophosphamide
Prednisolone
Dosage: on days 1-5; cycle 5
Doxorubicin Hydrochloride
Cyclophosphamide
Dosage: day 1; cycle 3
Indication: Mantle Cell Lymphoma
Cytarabine
Dosage: 3 or 2 g/m2, four-3 hour infusions; cycle 2
Cytarabine
Etoposide
Dosage: on days 2-5; beam/c regimen
Indication: Mantle Cell Lymphoma
Doxorubicin Hydrochloride
Indication: Mantle Cell Lymphoma
Vincristine
Dosage: day 1; cycle 3
Indication: Mantle Cell Lymphoma
Vincristine
Dosage: day 1; cycle 1
Cytarabine
Dosage: 3 or 2 g/m2, four-3 hour infusions;cycle 6
Rituximab
Dosage: given from cycle 5
Cyclophosphamide
Dosage: day 1; cycle 5
Prednisolone
Cytarabine
Dosage: 3 or 2 g/m2, four-3 hour infusions;cycle 4
Indication: Mantle Cell Lymphoma
Doxorubicin Hydrochloride
Rituximab
Dosage: given on day 1 from cycle 4
Indication: Mantle Cell Lymphoma
Carmustine
Dosage: on day 1; beam/c regimen
Indication: Mantle Cell Lymphoma
Possible Vincristine side effects in 46 year old female
Reported by a individual with unspecified qualification from United States on 2012-08-08
Patient: 46 year old female
Reactions: Dyspnoea, Pain in Extremity, Myelodysplastic Syndrome, General Physical Health Deterioration, Pyrexia, Pulmonary Haemorrhage, Zygomycosis, Diarrhoea, Skin Discolouration, Central Nervous System Infection, Small Intestinal Haemorrhage, Cough
Adverse event resulted in: death
Drug(s) suspected as cause:
Doxorubicin HCL
Indication: Diffuse Large B-Cell Lymphoma
Cyclophosphamide
Dosage: 400 ug, intravenous, every two months
Indication: Diffuse Large B-Cell Lymphoma
Melphalan (Melphalan) (Melphalen)
Indication: Diffuse Large B-Cell Lymphoma
Rituximab (Rituximab) (Rituximab)
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Idarubicin Hydrochloride
Indication: Diffuse Large B-Cell Lymphoma
Melphalan Hydrochloride
Indication: Diffuse Large B-Cell Lymphoma
Cytarabine
Indication: Diffuse Large B-Cell Lymphoma
Carmustine
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Carmustine
Indication: Diffuse Large B-Cell Lymphoma
Rituximab (Rituximab) (Rituximab)
Indication: Diffuse Large B-Cell Lymphoma
Possible Vincristine side effects in female
Reported by a health professional (non-physician/pharmacist) from France on 2012-08-01
Patient: female
Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome
Adverse event resulted in: life threatening event
Drug(s) suspected as cause:
Velcade
Indication: Multiple Myeloma
Start date: 2008-04-08
End date: 2008-09-01
Dexamethasone
Start date: 2008-04-08
Bicnu
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Doxorubicin Hydrochloride
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Cyclophosphamide
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Dexamethasone
Start date: 2008-06-01
End date: 2008-01-01
Prednisone
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Vincristine
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Alkeran
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Dexamethasone
Indication: Multiple Myeloma
Start date: 2008-05-05
Dexamethasone
Start date: 2008-05-19
Vepesid
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Possible Vincristine side effects in female
Reported by a health professional (non-physician/pharmacist) from France on 2012-08-01
Patient: female
Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome
Adverse event resulted in: life threatening event
Drug(s) suspected as cause:
Bicnu
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Alkeran
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Dexamethasone
Indication: Multiple Myeloma
Start date: 2004-01-01
End date: 2008-01-01
Cyclophosphamide
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Vepesid
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Dexamethasone
Start date: 2008-04-08
End date: 2008-09-01
Prednisone
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Vincristine
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Velcade
Indication: Multiple Myeloma
Start date: 2008-04-08
End date: 2008-06-01
Doxorubicin Hydrochloride
Indication: Multiple Myeloma
Start date: 2000-01-01
End date: 2000-01-01
Possible Vincristine side effects in male
Reported by a health professional (non-physician/pharmacist) from Italy on 2012-07-30
Patient: male
Reactions: Myelodysplastic Syndrome, Azotaemia
Adverse event resulted in: death
Drug(s) suspected as cause:
Doxorubicin Hydrochloride
Dosage: 380 mg
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2007-03-13
End date: 2007-05-17
Zevalin
Dosage: 1.6 mg
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2007-07-19
End date: 2007-07-19
Vincristine
Dosage: 8 mg
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2007-03-13
End date: 2007-05-17
Cyclophosphamide
Dosage: 5700 mg
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2007-03-13
End date: 2007-05-17
Possible Vincristine side effects in
Reported by a physician from United States on 2012-06-26
Patient:
Reactions: Death, Neoplasm Malignant, Burkitt's Lymphoma Recurrent, Myelodysplastic Syndrome, Burkitt's Leukaemia, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Indication: Acute Lymphocytic Leukaemia
Cyclophosphamide
Indication: Burkitt's Lymphoma
Methotrexate
Indication: Burkitt's Lymphoma
Cytarabine
Indication: Acute Lymphocytic Leukaemia
Monoclonal Antibodies
Dosage: standard dose
Indication: Acute Lymphocytic Leukaemia
Monoclonal Antibodies
Dosage: standard dose
Indication: Burkitt's Lymphoma
Rituximab
Dosage: days 1, 11 of hyper-cvad and days 1, 8 of mtx-cytarabine courses
Indication: Burkitt's Lymphoma
Doxorubicin HCL
Indication: Acute Lymphocytic Leukaemia
Doxorubicin HCL
Indication: Burkitt's Lymphoma
Dexamethasone
Indication: Burkitt's Lymphoma
Cytarabine
Indication: Burkitt's Lymphoma
Vincristine
Indication: Acute Lymphocytic Leukaemia
Vincristine
Indication: Burkitt's Lymphoma
Rituximab
Dosage: days 1, 11 of hyper-cvad and days 1, 8 of mtx-cytarabine courses
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Indication: Acute Lymphocytic Leukaemia
Other drugs received by patient: Unknown Medication
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-22
Patient:
Reactions: Myelodysplastic Syndrome, Mantle Cell Lymphoma
Drug(s) suspected as cause:
Rituximab
Dosage: before chemotherapy
Cytarabine
Dosage: 4 cycle of induction therapy
Indication: Mantle Cell Lymphoma
Rituximab
Dosage: again 7 days later
Indication: Mantle Cell Lymphoma
Cyclophosphamide
Dosage: 4 cycle of induction therapy
Indication: Mantle Cell Lymphoma
Vincristine
Dosage: 4 cycle of induction therapy
Indication: Mantle Cell Lymphoma
Prednisone TAB
Dosage: 4 cycle of induction therapy
Indication: Mantle Cell Lymphoma
Doxorubicin HCL
Dosage: 4 cycle of induction therapy
Indication: Mantle Cell Lymphoma
Methotrexate
Dosage: 4 cycle of induction therapy
Indication: Mantle Cell Lymphoma
Rituximab
Dosage: on days plus 1 and plus 8 after asct
Rituximab
Dosage: 4 cycle of induction therapy
Dexamethasone
Dosage: 4 cycle of induction therapy
Indication: Mantle Cell Lymphoma
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-12
Patient:
Reactions: Myelodysplastic Syndrome, Mantle Cell Lymphoma
Drug(s) suspected as cause:
Prednisone
Dosage: 4 cycle of induction therapy
Indication: Mantle Cell Lymphoma
Doxorubicin HCL
Dosage: 4 cycle of induction therapy
Indication: Mantle Cell Lymphoma
Rituximab
Dosage: again 7 days later
Indication: Mantle Cell Lymphoma
Cyclophosphamide
Dosage: 4 cycle of induction therapy
Indication: Mantle Cell Lymphoma
Rituximab
Dosage: before chemotherapy
Methotrexate
Dosage: 4 cycle of induction therapy
Indication: Mantle Cell Lymphoma
Rituximab
Dosage: 4 cycle of induction therapy
Cytarabine
Dosage: 4 cycle of induction therapy
Indication: Mantle Cell Lymphoma
Vincristine
Dosage: 4 cycle of induction therapy
Indication: Mantle Cell Lymphoma
Dexamethasone
Dosage: 4 cycle of induction therapy
Indication: Mantle Cell Lymphoma
Possible Vincristine side effects in
Reported by a physician from United States on 2012-06-12
Patient:
Reactions: Death, Burkitt's Lymphoma Recurrent, Neoplasm Malignant, Myelodysplastic Syndrome, Burkitt's Leukaemia, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Doxorubicin HCL
Indication: Burkitt's Lymphoma
Vincristine
Indication: Burkitt's Lymphoma
Methotrexate
Indication: Burkitt's Lymphoma
Monoclonal Antibodies
Dosage: standard dose
Indication: Burkitt's Lymphoma
Cytarabine
Indication: Acute Lymphocytic Leukaemia
Monoclonal Antibodies
Dosage: standard dose
Indication: Acute Lymphocytic Leukaemia
Rituximab
Dosage: days 1, 11 of hyper-cvad and days 1, 8 of mtx-cytarabine courses
Indication: Acute Lymphocytic Leukaemia
Cyclophosphamide
Indication: Acute Lymphocytic Leukaemia
Doxorubicin HCL
Indication: Acute Lymphocytic Leukaemia
Cyclophosphamide
Indication: Burkitt's Lymphoma
Cytarabine
Indication: Burkitt's Lymphoma
Rituximab
Dosage: days 1, 11 of hyper-cvad and days 1, 8 of mtx-cytarabine courses
Indication: Burkitt's Lymphoma
Dexamethasone
Indication: Acute Lymphocytic Leukaemia
Dexamethasone
Indication: Burkitt's Lymphoma
Vincristine
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Indication: Acute Lymphocytic Leukaemia
Other drugs received by patient: Unknown Medication
Possible Vincristine side effects in
Reported by a physician from Germany on 2012-06-01
Patient:
Reactions: Respiratory Disorder, Pain, Myelodysplastic Syndrome, Pyrexia, Neoplasm, Death, Completed Suicide, Thrombocytopenia, Vomiting, Nausea, Anaemia, Acute Myeloid Leukaemia, Toxicity To Various Agents, Haematotoxicity, Hodgkin's Disease, Mucosal Inflammation, Accident, Alopecia, Gastrointestinal Disorder, Nervous System Disorder, non-Hodgkin's Lymphoma, Cardiovascular Disorder, Leukopenia, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Hodgkin's Disease
Etoposide
Indication: Hodgkin's Disease
Vincristine
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Indication: Hodgkin's Disease
Prednisone TAB
Indication: Hodgkin's Disease
Doxorubicin HCL
Indication: Hodgkin's Disease
Bleomycin Sulfate
Indication: Hodgkin's Disease
Other drugs received by patient: Radiotherapy
Possible Vincristine side effects in 55 year old female
Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-05-31
Patient: 55 year old female
Reactions: Myelodysplastic Syndrome, Pancytopenia, Anaemia Megaloblastic
Drug(s) suspected as cause:
Methotrexate
Dosage: 15 mg, weekly
Indication: Acute Lymphocytic Leukaemia
Vincristine
Dosage: 2- 3 mg, monthly
Indication: Acute Lymphocytic Leukaemia
Daunorubicin HCL
Indication: Acute Lymphocytic Leukaemia
Etoposide
Indication: Acute Lymphocytic Leukaemia
Mercaptopurine
Dosage: 50 mg, udaily
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Indication: Acute Lymphocytic Leukaemia
Possible Vincristine side effects in 66 year old female
Reported by a physician from United States on 2012-05-25
Patient: 66 year old female
Reactions: Refractory Anaemia With AN Excess of Blasts, Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Bone Marrow Toxicity
Adverse event resulted in: death
Drug(s) suspected as cause:
Temozolomide
Indication: Oligodendroglioma
Lomustine
Indication: Oligodendroglioma
Carmustine
Indication: Oligodendroglioma
Procarbazine Hydrochloride
Indication: Oligodendroglioma
Vincristine
Indication: Oligodendroglioma
Possible Vincristine side effects in 11 year old male
Reported by a physician from United States on 2012-05-24
Patient: 11 year old male
Reactions: Myelodysplastic Syndrome, Treatment Related Secondary Malignancy
Adverse event resulted in: death
Drug(s) suspected as cause:
Temozolomide
Indication: Brain Neoplasm
Etoposide
Indication: Brain Neoplasm
Procarbazine Hydrochloride
Indication: Brain Neoplasm
Cyclophosphamide
Indication: Brain Neoplasm
Cisplatin
Indication: Brain Neoplasm
Carboplatin
Indication: Brain Neoplasm
Vincristine
Indication: Brain Neoplasm
Possible Vincristine side effects in 70 year old female
Reported by a physician from Japan on 2012-05-11
Patient: 70 year old female
Reactions: Myelodysplastic Syndrome
Adverse event resulted in: life threatening event
Drug(s) suspected as cause:
Mabthera
Dosage: unknown
Indication: Product Used FOR Unknown Indication
Ibritumomab Tiuxetan
Dosage: unknown
Indication: Product Used FOR Unknown Indication
Start date: 2009-04-08
Cladribine
Dosage: unknown
Indication: Product Used FOR Unknown Indication
Mitoxantrone
Dosage: unknown
Indication: Product Used FOR Unknown Indication
Cyclophosphamide
Dosage: unknown
Indication: Product Used FOR Unknown Indication
Doxorubicin Hydrochloride
Dosage: unknown
Indication: Product Used FOR Unknown Indication
Vincristine
Dosage: unknown
Indication: Product Used FOR Unknown Indication
Prednisolone
Dosage: unknown
Indication: Product Used FOR Unknown Indication
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from France on 2012-05-10
Patient:
Reactions: Myelodysplastic Syndrome
Drug(s) suspected as cause:
Fludarabine Phosphate
Indication: Chronic Lymphocytic Leukaemia
Granulocyte Colony Stimulating Factor
Indication: Chronic Lymphocytic Leukaemia
Cyclophosphamide
Indication: Chronic Lymphocytic Leukaemia
Prednisone TAB
Administration route: Oral
Indication: Chronic Lymphocytic Leukaemia
Doxorubicin HCL
Indication: Chronic Lymphocytic Leukaemia
Vincristine
Indication: Chronic Lymphocytic Leukaemia
Other drugs received by patient: Valacyclovir Hydrochloride; Acyclovir; Cotrim; Blood Product
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from France on 2012-05-10
Patient:
Reactions: Lung Neoplasm Malignant, Myelodysplastic Syndrome
Drug(s) suspected as cause:
Cyclophosphamide
Cladribine
Indication: Chronic Lymphocytic Leukaemia Recurrent
Prednisone TAB
Administration route: Oral
Indication: Chronic Lymphocytic Leukaemia
Radiation Therapy NOS
Indication: Chronic Lymphocytic Leukaemia
Doxorubicin HCL
Indication: Chronic Lymphocytic Leukaemia
Granulocyte Colony Stimulating Factor
Indication: Chronic Lymphocytic Leukaemia
Cyclophosphamide
Dosage: on 2 successive days
Cyclophosphamide
Indication: Chronic Lymphocytic Leukaemia
Fludarabine Phosphate
Indication: Chronic Lymphocytic Leukaemia
Vincristine
Indication: Chronic Lymphocytic Leukaemia
Rituximab
Indication: Chronic Lymphocytic Leukaemia Recurrent
Other drugs received by patient: Valacyclovir Hydrochloride; Acyclovir; Cotrim; Blood Products
Possible Vincristine side effects in
Reported by a individual with unspecified qualification from United States on 2012-05-09
Patient:
Reactions: Death, Metastasis, Acute Myeloid Leukaemia, Myelodysplastic Syndrome, Haematotoxicity
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: non-Hodgkin's Lymphoma
Vincristine
Indication: non-Hodgkin's Lymphoma
Mabthera
Indication: non-Hodgkin's Lymphoma
Prednisone TAB
Indication: non-Hodgkin's Lymphoma
Doxorubicin HCL
Indication: non-Hodgkin's Lymphoma
Possible Vincristine side effects in 66 year old female
Reported by a individual with unspecified qualification from Japan on 2012-05-08
Patient: 66 year old female
Reactions: White Blood Cell Count Decreased, Platelet Count Decreased, Myelodysplastic Syndrome
Drug(s) suspected as cause:
Mabthera
Dosage: 250 mg/m2, single
Indication: B-Cell Lymphoma
Cyclophosphamide
Indication: Product Used FOR Unknown Indication
Prednisolone
Indication: Product Used FOR Unknown Indication
Mitoxantrone Hydrochloride
Indication: Product Used FOR Unknown Indication
Ibritumomab Tiuxetan
Dosage: 130 mbq, single
Vincristine
Indication: Product Used FOR Unknown Indication
Cladribine
Indication: Product Used FOR Unknown Indication
Ibritumomab Tiuxetan
Dosage: 11.1 mbq/kg, unk
Indication: B-Cell Lymphoma
Doxorubicin HCL
Indication: Product Used FOR Unknown Indication
Other drugs received by patient: Adona; Mucosta; Basen; Acetaminophen; Amaryl; Losartan Potassium; Allegra
Possible Vincristine side effects in
Reported by a physician from United States on 2012-04-24
Patient:
Reactions: Death, B-Cell Lymphoma, Neoplasm Malignant, Acute Myeloid Leukaemia, Adverse Event, Myelodysplastic Syndrome, Haematotoxicity
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: for 5 days at 3 week interval
Indication: B-Cell Lymphoma
Tositumomab
Dosage: for 5 days at 3 week interval
Indication: B-Cell Lymphoma
Vincristine
Dosage: for 5 days at 3 week interval
Indication: B-Cell Lymphoma
Doxorubicin HCL
Dosage: for 5 days at 3 week interval
Indication: B-Cell Lymphoma
Rituximab
Dosage: for 5 days at 3 week interval
Indication: B-Cell Lymphoma
Tositumomab-Iodine 131
Dosage: dosimetric
Indication: B-Cell Lymphoma
Prednisone TAB
Dosage: for 5 days at 3 week interval
Indication: B-Cell Lymphoma
Tositumomab-Iodine 131
Dosage: therapeutic
Possible Vincristine side effects in 57 year old male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-04-24
Patient: 57 year old male
Reactions: Stem Cell Transplant, Dyspnoea, T-Cell Type Acute Leukaemia, Acquired Diaphragmatic Eventration, Hairy Cell Leukaemia, Myelodysplastic Syndrome, Pleural Effusion, Leukaemia Recurrent, Treatment Related Secondary Malignancy
Drug(s) suspected as cause:
Dexamethasone
Indication: T-Cell Type Acute Leukaemia
Start date: 2009-01-01
End date: 2009-01-01
Adriamycin PFS
Indication: T-Cell Type Acute Leukaemia
Start date: 2009-01-01
End date: 2009-01-01
Cyclophosphamide
Indication: T-Cell Type Acute Leukaemia
Start date: 2009-01-01
End date: 2009-01-01
Vincristine
Indication: T-Cell Type Acute Leukaemia
Start date: 2009-01-01
End date: 2009-01-01
Cladribine
Indication: Hairy Cell Leukaemia
Start date: 2005-01-01
End date: 2005-01-01
Cladribine
Indication: Hairy Cell Leukaemia
Start date: 2009-01-01
End date: 2009-01-01
Possible Vincristine side effects in 49 year old female
Reported by a health professional (non-physician/pharmacist) from Serbia on 2012-04-24
Patient: 49 year old female
Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome
Adverse event resulted in: death
Drug(s) suspected as cause:
Prednisolone
Dosage: unk
Indication: Chronic Lymphocytic Leukaemia
Cyclophosphamide
Dosage: 200 mg/m2, for 3 conseq.days, q 28 days x 6 cycles
Indication: Chronic Lymphocytic Leukaemia
Adriamycin PFS
Dosage: unk
Indication: Chronic Lymphocytic Leukaemia
Fludarabine Phosphate
Dosage: 25 mg/m2, for 3 conseq. days, q 28 days x 6 cycles
Indication: Chronic Lymphocytic Leukaemia
Vincristine
Dosage: unk
Indication: Chronic Lymphocytic Leukaemia
Possible Vincristine side effects in 54 year old male
Reported by a health professional (non-physician/pharmacist) from Serbia on 2012-04-24
Patient: 54 year old male
Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome
Adverse event resulted in: death
Drug(s) suspected as cause:
Prednisolone
Dosage: unk
Indication: Chronic Lymphocytic Leukaemia
Cyclophosphamide
Dosage: 200 mg/m2, for 3 conseq.days, q 28 days x 6 cycles
Indication: Chronic Lymphocytic Leukaemia
Fludarabine Phosphate
Dosage: 25 mg/m2, for 3 conseq. days, q 28 days x 6 cycles
Indication: Chronic Lymphocytic Leukaemia
Mitoxantrone
Dosage: unk
Indication: Chronic Lymphocytic Leukaemia
Adriamycin PFS
Dosage: unk
Indication: Chronic Lymphocytic Leukaemia
Dexamethasone
Dosage: unk
Indication: Chronic Lymphocytic Leukaemia
Vincristine
Dosage: unknown
Indication: Chemotherapy
Possible Vincristine side effects in male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-04-17
Patient: male
Reactions: Myelodysplastic Syndrome
Adverse event resulted in: death
Drug(s) suspected as cause:
Doxorubicin HCL
Bleomycin Sulfate
Etoposide
Cyclophosphamide
Cyclophosphamide
Vincristine
Vincristine
Vincristine
Procarbazine Hydrochloride
Administration route: Oral
Procarbazine Hydrochloride
Administration route: Oral
Doxorubicin HCL
Bleomycin Sulfate
Etoposide
Cyclophosphamide
Vincristine
Vincristine
Prednisone TAB
Administration route: Oral
Bleomycin Sulfate
Etoposide
Vincristine
Procarbazine Hydrochloride
Administration route: Oral
Indication: Hodgkin's Disease Stage III
Procarbazine Hydrochloride
Administration route: Oral
Doxorubicin HCL
Bleomycin Sulfate
Bleomycin Sulfate
Vincristine
Procarbazine Hydrochloride
Administration route: Oral
Procarbazine Hydrochloride
Administration route: Oral
Doxorubicin HCL
Indication: Hodgkin's Disease Stage III
Doxorubicin HCL
Doxorubicin HCL
Etoposide
Cyclophosphamide
Prednisone TAB
Administration route: Oral
Indication: Hodgkin's Disease Stage III
Prednisone TAB
Administration route: Oral
Procarbazine Hydrochloride
Administration route: Oral
Radiotherapy
Indication: Hodgkin's Disease Stage III
Doxorubicin HCL
Bleomycin Sulfate
Indication: Hodgkin's Disease Stage III
Bleomycin Sulfate
Bleomycin Sulfate
Etoposide
Indication: Hodgkin's Disease Stage III
Etoposide
Cyclophosphamide
Indication: Hodgkin's Disease Stage III
Cyclophosphamide
Prednisone TAB
Administration route: Oral
Prednisone TAB
Administration route: Oral
Etoposide
Prednisone TAB
Administration route: Oral
Doxorubicin HCL
Etoposide
Cyclophosphamide
Cyclophosphamide
Vincristine
Indication: Hodgkin's Disease Stage III
Prednisone TAB
Administration route: Oral
Prednisone TAB
Administration route: Oral
Procarbazine Hydrochloride
Administration route: Oral
Other drugs received by patient: Neupogen
Possible Vincristine side effects in 49 year old female
Reported by a health professional (non-physician/pharmacist) from Serbia on 2012-04-16
Patient: 49 year old female
Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome
Drug(s) suspected as cause:
Fludarabine Phosphate
Dosage: 25 mg/m2, intravenous (not otherwise specified)
Indication: Chronic Lymphocytic Leukaemia Stage 2
Cyclophosphamide
Dosage: 200 mg/m2, intravenous (not otherwise specified)
Indication: Chronic Lymphocytic Leukaemia Stage 2
Vincristine
Indication: Chronic Lymphocytic Leukaemia Stage 2
Adriamycin PFS
Indication: Chronic Lymphocytic Leukaemia Stage 2
Prednisolone
Indication: Chronic Lymphocytic Leukaemia Stage 2
Possible Vincristine side effects in 54 year old male
Reported by a health professional (non-physician/pharmacist) from Serbia on 2012-04-16
Patient: 54 year old male
Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome
Drug(s) suspected as cause:
Adriamycin PFS
Indication: Chronic Lymphocytic Leukaemia Stage 3
Vincristine
Indication: Chronic Lymphocytic Leukaemia Stage 3
Dexamethasone
Indication: Chronic Lymphocytic Leukaemia Stage 3
Prednisolone
Indication: Chronic Lymphocytic Leukaemia Stage 3
Fludarabine Phosphate
Dosage: 25 mg/m2, intravenous (not otherwise specified)
Indication: Chronic Lymphocytic Leukaemia Stage 3
Mitoxantrone
Indication: Chronic Lymphocytic Leukaemia Stage 3
Cyclophosphamide
Dosage: 200 mg/m2, intravenous (not otherwise specified)
Indication: Chronic Lymphocytic Leukaemia Stage 3
Possible Vincristine side effects in 54 year old male
Reported by a health professional (non-physician/pharmacist) from Serbia on 2012-04-13
Patient: 54 year old male
Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome
Adverse event resulted in: death
Drug(s) suspected as cause:
Mitoxantrone
Indication: Chronic Lymphocytic Leukaemia
Dexamethasone
Indication: Chronic Lymphocytic Leukaemia
Fludarabine Phosphate
Dosage: therapy for 3 consecutive days in each 28day cycle. fnd therapy 4 cycles
Indication: Chronic Lymphocytic Leukaemia
Prednisolone
Indication: Chronic Lymphocytic Leukaemia
Vincristine
Dosage: chop 2 cycles
Indication: Chronic Lymphocytic Leukaemia
Cyclophosphamide
Dosage: therapy for 3 consecutive days in each 28day cycle.chop therapy 2 cycles
Indication: Chronic Lymphocytic Leukaemia
Adriamycin PFS
Dosage: chop 2 cycles
Indication: Chronic Lymphocytic Leukaemia
Possible Vincristine side effects in 49 year old female
Reported by a health professional (non-physician/pharmacist) from Serbia on 2012-04-13
Patient: 49 year old female
Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome
Adverse event resulted in: death
Drug(s) suspected as cause:
Fludarabine Phosphate
Dosage: therapy for 3 conescutive days in each 28day cycle.
Indication: Chronic Lymphocytic Leukaemia
Adriamycin PFS
Dosage: chop 6 cycles
Indication: Chronic Lymphocytic Leukaemia
Cyclophosphamide
Dosage: therapy for 3 consecutive days in each 28day cycle.chop=6cycles
Indication: Chronic Lymphocytic Leukaemia
Prednisolone
Dosage: chop =6cycle
Indication: Chronic Lymphocytic Leukaemia
Vincristine
Dosage: chop 6 cycles
Indication: Chronic Lymphocytic Leukaemia
Possible Vincristine side effects in 54 year old male
Reported by a health professional (non-physician/pharmacist) from Serbia on 2012-04-04
Patient: 54 year old male
Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome
Drug(s) suspected as cause:
Prednisolone
Indication: Chronic Lymphocytic Leukaemia
Vincristine
Indication: Chronic Lymphocytic Leukaemia
Adriamycin PFS
Indication: Chronic Lymphocytic Leukaemia
Cyclophosphamide
Dosage: 200 mg/meter square
Indication: Chronic Lymphocytic Leukaemia
Mitoxantrone
Indication: Chronic Lymphocytic Leukaemia
Fludarabine Phosphate
Dosage: 25 mg/meter square
Indication: Chronic Lymphocytic Leukaemia
Dexamethasone
Indication: Chronic Lymphocytic Leukaemia
Possible Vincristine side effects in 49 year old female
Reported by a individual with unspecified qualification from Serbia on 2012-04-04
Patient: 49 year old female
Reactions: Acute Myeloid Leukaemia, Myelodysplastic Syndrome
Drug(s) suspected as cause:
Adriamycin PFS
Vincristine
Fludarabine Phosphate
Prednisolone
Cyclophosphamide
Page 1 Next >>
|